Integrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity
Fig 2
Relationship between HuR and patients’ outcome was estimated with pan-cancer overall survival (OS) analysis.
Log-rank test OS analysis of HuR was displayed with survival curve in different cancer types, including ACC (A), BRCA (B), GBM-LGG (C), LGG (D), LIHC (E), LUAD (F), MESO (G), PAAD (H), SARC (I), and SKCM (J).